Perceptive Discovery announced a strategic partnership with MH3D alongside the launch of α-Sight™, a new preclinical imaging offering enabling direct, in vivo visualization of alpha-emitting radiopharmaceuticals.
Alpha-emitting therapies are rapidly transforming oncology, but limitations in imaging have made it difficult to fully characterize biodistribution and therapeutic impact. α-Sight™ addresses this challenge with high-sensitivity, quantitative whole-body imaging, providing earlier, more accurate insight into alpha therapy behavior.
The offering integrates MH3D’s Alpha-SPECT Mini platform with Perceptive Discovery’s expertise in preclinical imaging, radiochemistry, and advanced image analysis. Through the partnership, Perceptive Discovery will serve as MH3D’s exclusive service provider, while collaborating on product enhancements and expanding isotope imaging datasets.
“At Perceptive Discovery, nuclear medicine is in our DNA,” said Ben Murphy, CEO of Perceptive Discovery. “By combining MH3D’s innovative imaging technology with our scientific and analytical expertise, α-Sight™ enables our clients to generate deeper insight and make faster development decisions for alpha therapies.”
Also Read: North Star Imaging Redefines CT Visualization with Launch of efX 3.0 Software
Powered by advanced CZT-based detection, the Alpha-SPECT™ Mini supports multi-isotope imaging, longitudinal study design, and precise quantification, enabling robust evaluation of therapies such as Actinium-225 and Astatine-211.
A key differentiator of α-Sight™ is its integration with VivoQuant™, Perceptive Discovery’s quantitative imaging platform, which enables advanced analysis workflows and transforms imaging data into decision-ready insights.
“Perceptive Discovery brings deep expertise across imaging, radiochemistry, and image analysis, making them an ideal partner to advance the application of Alpha-SPECT™ technology,” said Xiaopei Huang, CEO and Founder at MH3D.
α-Sight™ supports a range of applications, including biodistribution studies, tumor targeting validation, and PK/PD assessment, helping accelerate candidate selection and de-risk radioligand therapy development programs.
SOURCE: PRNewswire
